Join to View Full Profile
4383 Medical DrSan Antonio, TX 78229
Phone+1 210-593-5700
Fax+1 210-593-5992
Dr. Patnaik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Toronto Faculty of MedicineClass of 1992
Certifications & Licensure
TX State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02) Start of enrollment: 2007 May 01
- Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Jan 01
- A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors Start of enrollment: 2013 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors.Cathy Eng, Nehal J Lakhani, Philip A Philip, Charles Schneider, Benny Johnson
Targeted Oncology. 2025-03-26 - Myeloid targeting antibodies PY159 and PY314 for platinum-resistant ovarian cancer.Oladapo O Yeku, Minal Barve, Winston W Tan, Judy Wang, Amita Patnaik
Journal for Immunotherapy of Cancer. 2025-03-13 - CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid t...J Randolph Hecht, Jean-Marie Michot, David Bajor, Amita Patnaik, Ki Y Chung
BJC Reports. 2025-02-27
Press Mentions
selfBACK App Developed by Norwegian University of Science Can Help Relieve Back PainAugust 3rd, 2021- START Launches New Phase I Clinical Trial Program in UtahJune 8th, 2021
- Nektar Therapeutics Announces Its First Publication of Preclinical Data Highlighting Anti-Tumor Properties of IL-15 Agonist, NKTR-255, in the Journal for ImmunoTherapy of Cancer (JITC)May 18th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
